Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 4.6% Higher – What’s Next?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s share price traded up 4.6% during mid-day trading on Friday . The stock traded as high as $6.20 and last traded at $6.22. 4,144,273 shares traded hands during trading, a decline of 60% from the average session volume of 10,307,810 shares. The stock had previously closed at $5.94.

Wall Street Analyst Weigh In

RXRX has been the subject of several research reports. KeyCorp cut their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Leerink Partners cut their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research note on Friday, February 28th. Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $8.25.

Recursion Pharmaceuticals Trading Up 6.9 %

The firm has a 50 day simple moving average of $7.54 and a 200 day simple moving average of $7.02. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The firm has a market cap of $2.55 billion, a P/E ratio of -4.15 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. During the same quarter in the prior year, the business earned ($0.42) EPS. The firm’s revenue for the quarter was down 57.8% compared to the same quarter last year. On average, equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Institutional Trading of Recursion Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Decker Retirement Planning Inc. purchased a new stake in shares of Recursion Pharmaceuticals in the 4th quarter valued at about $26,000. Private Trust Co. NA purchased a new stake in shares of Recursion Pharmaceuticals in the 4th quarter valued at about $27,000. GAMMA Investing LLC raised its holdings in shares of Recursion Pharmaceuticals by 1,979.2% in the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock valued at $35,000 after acquiring an additional 4,948 shares in the last quarter. KBC Group NV raised its holdings in shares of Recursion Pharmaceuticals by 79.9% in the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after acquiring an additional 3,377 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its holdings in shares of Recursion Pharmaceuticals by 21.1% during the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock valued at $52,000 after buying an additional 1,353 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.